Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It seems a fair offer at £13.50 looking at recent SP history so I will be accepting that. From the RNS, they are also hoping to complete the transaction during Q1 2024.
I wasn't aware of any acquisition talks ongoing and so not aware if there is any likelihood of another bidder entering the fray.
Didn't see that coming. Ergomed has been a cracking investment and proof that holding long on AIM can work out. Look forward to watching from a distance and hope they continue to go from strength to strength.
Yep an impressive update, particularly in the current enviroment.
Strong growth announcement.
Let’s hope we see it reflected in the SP which has been a bit subdued.
Still a great long term investment though in my opinion.
This is a frustrating investment currently. The recent results were by any parameters good, yet even allowing for the recent general market volatility, the share price has been hammered.
Pharma shares on AIM are notoriously volatile yet this isn’t a company trying to bring a drug through development or trial, their effective ‘support’ facilities to that sector are in high demand.
Future Order / Work pipeline is a big number, No debt, Cash still strong ( reduction on previous year easily explained by the Adamas acquisition).
EPS only marginally increased, perhaps the MM’s and Analysts were disappointed with that figure but that seems unlikely.
I’m nursing a bigger paper loss on this investment that I would normally tolerate, but like fellow commentators I still see this as an excellent medium term growth stock. Just currently frustrating, so guess go with the proverbial ups and downs of investing.
Good tick up today,not sure why but I won’t complain.
Hoping to add £20,000 in here in this years ISA allowance if things go to plan and I see this as a 5-10 year investment. Very strong growth potential and with relatively little risk as far as I can see.
Interesting and a very bright future ahead in my opinion.
Yes, very solid figures. Share price today doesn't reflect that but a potential buying opportunity for those like myself who see this as a strong long term portfolio hold.
I believe their organic and acquisition growth strategy will continue, they could be a potential acquisition target themselves at some future date, although I personally don’t see that as a short / medium term possibility. IMHO
Yep another strong update.
Richard Barfield has been a great asset, I'll be sorry to see him go and wish him well in his retirement. Great succession planning though with a smooth transition to another high quality CFO.
Yep, great company. Never fails to impress.
Is this a ‘sale the news’ like so many other decent updates lately? Sigh.
Strong figures again today.
Good solid future.
RNS this morning looks very positive.
Certainly strengthening the team and hopefully taking the company forward.
Can see the SP being 1400 plus pretty soon.
Well we got there but it wasn’t really unexpected on the good figures supplied. Can we continue the momentum into the next few months. Difficult to say with what’s going on around us but it really should be getting back to recent highs. Good luck.
Some pretty decent buying over the last couple of days.
Lets hope it continues next and and we see 1300 plus.
One can but hope, but in my honest opinion its actualy pretty likely in the near term.
Have a good weekend and fingers crossed for the Lionesses.
Excellent update today from Ergomed. strong revenue and order book growth with £12 cash after the purchase of Adamas and debt free. Note the increase in the RCF to £80m - seems they are still very much in acquisitive mode.
Excellent growth.
Hopefully the SP will return to a higher level on these rather outstanding figures.
· Revenue £118.6 million up 37.3%
· Adjusted EBITDA £25.4 million up 31.2%
· Forward visibility underpinned by strong order book of £239.7 million up 24.2%
· Further strengthening of US strategic presence with US revenues up 59.5%
· Year-end net cash balance of £31.2 million up 64.5%
Strong growth in America and Asia.
Excellent progression.
Buying pressure full on.
People seem to be coming in again ready for results in just four weeks time. Ive added first thing this morning with another 650 shares.